Radiation is often thought of as dangerous and unhealthy. It is, of course, when it’s improperly used, and history has done a very good job of showing us what [...]
Molybdenum-99 (Mo-99) is the radioactive isotope that enables many diagnostic nuclear medicine procedures such as SPECT scans, which can detect many potentially life-threatening conditions and help patients receive the potentially [...]
Our isotope production process is enabling treatment options that have the potential to improve outcomes for patients being treated for a range of cancers. Our current focus includes production [...]
SHINE Medical Technologies LLC today announced that it has entered a multi-year contract with the University of Missouri Research Reactor, or MURR®, for irradiation of ytterbium-176.
SHINE Medical Technologies LLC today announced that they have entered into a distribution agreement enabling EDH to act as a SHINE-authorized distributor for selected countries
SHINE Medical Technologies LLC today announced that it has selected the municipality of Veendam in the province of Groningen, the Netherlands, as the location of its European medical isotope production facility. The decision is the culmination of a year-long search process that included the review of more than 50 proposals from sites across Europe.
SHINE Medical Technologies LLC and Von Gahlen International Inc. today announced that Von Gahlen will build and install the “supercell,” a bank of 10 hot cells, for SHINE’s U.S. medical isotope production facility in Janesville, Wis.
SHINE announced that its Therapeutics division has made its first commercial sales of lutetium-177 to multiple customers. Lutetium-177, or Lu-177, is a therapeutic isotope in demand by clinical trial sponsors because of its potential to revolutionize the treatment of cancer patients.
SHINE Medical Technologies LLC, the Institute of Organic Chemistry and Biochemistry (IOCB Prague) and GE Healthcare today announced the production of patient doses of the therapeutic isotope lutetium-177 (Lu-177).
SHINE Medical Technologies today announced the creation of a new division of the company — SHINE Therapeutics. The establishment of the division enhances the company’s ability to focus on filling critical future needs in the rapidly growing therapeutic isotope market, while continuing to leverage its radioisotope production expertise.